3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
4
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Trastuzumab
20
Radiosurgery
15
Magnetic Resonance Spectroscopy
15
Capecitabine
14
Lapatinib
12
Radiotherapy
11
Specimen Handling
10
Cyclophosphamide
9
trastuzumab deruxtecan
8
Temozolomide
8
Docetaxel
8
Paclitaxel
7
Gemcitabine
6
Cisplatin
6
sacituzumab govitecan
5
Vinorelbine
5
Therapeutics
5
Spinal Puncture
5
Flow Cytometry
5
tucatinib
4
pembrolizumab
4
paclitaxel-Angiopep-2 conjugate
4
eribulin
4
Methotrexate
4
Irinotecan
4
Fluorodeoxyglucose F18
4
Dexamethasone
4
Bevacizumab
4
temsirolimus
3
pyrotinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Doxycycline
×
CNS
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn